Comparison between Mono Pharmacare IPO and Saroja Pharma IPO.
Mono Pharmacare IPO is a SME Fixed Price IPO proposed to list at NSE SME while Saroja Pharma IPO is a SME Fixed Price proposed to list at NSE SME.
| Mono Pharmacare IPO | Saroja Pharma IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Unistone Capital Pvt.Ltd. | Swastika Investmart Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | Rikhav Securities Ltd. | Swastika Investmart Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | ||
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Mono Pharmacare IPO is up to ₹14.07 Cr whereas the issue size of the Saroja Pharma IPO is up to ₹8.66 Cr. The final issue price of Mono Pharmacare IPO is ₹28.00 per share and of Saroja Pharma IPO is ₹84.00 per share.
| Mono Pharmacare IPO | Saroja Pharma IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹26.00 per share | |
| Issue Price (Upper) | ₹28.00 per share | |
| Issue Price (Final) | ₹28.00 per share | ₹84.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 4000 shares | 1600 shares |
| Fresh Issue Size | 50,24,000 shares | 10,30,400 shares |
| Fresh Issue Size (Amount) | up to ₹14.07 Cr | up to ₹8.66 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 50,24,000 shares | 10,30,400 shares |
| Issue Size Total (Amount) | up to ₹14.07 Cr | up to ₹8.66 Cr |
Mono Pharmacare IPO opens on Aug 28, 2023, while Saroja Pharma IPO opens on Aug 31, 2023. The closing date of Mono Pharmacare IPO and Saroja Pharma IPO is Aug 30, 2023, and Sep 05, 2023, respectively.
| Mono Pharmacare IPO | Saroja Pharma IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Aug 28, 2023 | Aug 31, 2023 |
| Issue Close | Aug 30, 2023 | Sep 05, 2023 |
| Basis Of Allotment (Tentative) | Sep 04, 2023 | Sep 08, 2023 |
| Initiation of Refunds (Tentative) | Sep 05, 2023 | Sep 11, 2023 |
| Credit of Share (Tentative) | Sep 06, 2023 | Sep 12, 2023 |
| Listing date (Tentative) | Sep 07, 2023 | Sep 13, 2023 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Mono Pharmacare IPO P/E ratio is , as compared to Saroja Pharma IPO P/E ratio of 23.25.
| Mono Pharmacare IPO | Saroja Pharma IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Standalone)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 81.02 | 100.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 23.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹49.47 Cr. | ₹33.77 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 9.01% | 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 10.34% | 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.92 | 2.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹1.99 | ₹3.61 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 9.01% | 20.85 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Mono Pharmacare IPO Retail Individual Investors (RII) are offered 22,64,000 shares while in Saroja Pharma IPO retail investors are offered 22,64,000 shares. Qualified Institutional Buyers (QIB) are offered 5,00,000 shares in Mono Pharmacare IPO and in Saroja Pharma IPO.
| Mono Pharmacare IPO | Saroja Pharma IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | 2,76,000 shares | 54,400 shares |
| QIB | 5,00,000 shares | |
| NII | 22,60,000 shares | 5,15,200 shares |
| RII | 22,64,000 shares | 5,15,200 shares |
| Employee | ||
| Others | ||
| Total | 50,24,000 shares | 10,30,400 shares |
Mono Pharmacare IPO subscribed 13.42x in total, whereas Saroja Pharma IPO subscribed 8.88x.
| Mono Pharmacare IPO | Saroja Pharma IPO | |
|---|---|---|
| QIB (times) | 10.89x | |
| NII (times) | 8.00x | 2.90x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 19.40x | 14.83x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 13.42x | 8.88x |
